Health Monthly Martinique: Press Releases

Browse our comprehensive archive of press releases by date.
Select a specific day to access all press releases published on Health Monthly Martinique.

Press releases published on June 2, 2026

Jun. 2, 2026

The Ensign Group Purchases Memory Care Facility in California

Indeterminate GlobeNewswire

Jun. 2, 2026

Herantis reports positive FDA feedback and finalizes Phase 2a study design for HER-096

Indeterminate GlobeNewswire

Jun. 2, 2026

Propanc Biopharma’s CEO Attends Keynote Address, “Rejuvenation and Health: Science for an Ageing Society,” at the University of Granada, Spain

Indeterminate GlobeNewswire

Jun. 2, 2026

Crinetics’ Paradigm-Shifting Portfolio and Pipeline on Display at ENDO 2026 with Six Presentations

Indeterminate GlobeNewswire

Jun. 2, 2026

Philips announces exchange ratio for 2025 dividend

Indeterminate GlobeNewswire

Jun. 2, 2026

Comen Launches Latin American Medical Solutions at Hospitalar 2026

Indeterminate GlobeNewswire

Jun. 2, 2026

FundaMental Pharma appoints depression drug developer Dr. Hans Eriksson as Chief Medical Officer to advance its lead treatment-resistant depression candidate

Indeterminate GlobeNewswire

Jun. 2, 2026

Nanobiotix Joins the Euronext Tech Leaders Index

Indeterminate GlobeNewswire

Jun. 2, 2026

Nanobiotix rejoint l'indice Euronext Tech Leaders

Indeterminate GlobeNewswire

Jun. 2, 2026

OXB Capital Markets Event

Indeterminate GlobeNewswire

Jun. 2, 2026

Greywolf Therapeutics reports durable clinical responses with first-in-class oral ERAP1 inhibitor GRWD5769 across six solid tumor types

Indeterminate GlobeNewswire

Jun. 2, 2026

Launch of TechBio firm, Lucera, brings decision intelligence to drug development, making it more predictable, more evidence-grounded, and more efficient

Indeterminate GlobeNewswire

Jun. 2, 2026

Inventiva Announces Temporary Trading Halt of its Ordinary Shares on Euronext Paris

Indeterminate GlobeNewswire

Jun. 2, 2026

Inventiva annonce la suspension temporaire du cours de ses actions ordinaires sur Euronext Paris

Indeterminate GlobeNewswire

Jun. 2, 2026

Santhera gibt die Erteilung des Orphan-Drug-Status und der Prioritätsprüfung für AGAMREE® (Vamorolon) in Südkorea bekannt

Indeterminate GlobeNewswire

Jun. 2, 2026

Santhera Announces Orphan Drug and Priority Review Designations for AGAMREE® (Vamorolone) in South Korea

Indeterminate GlobeNewswire

Jun. 2, 2026

Rapid Nutrition Expands Agentic AI Integration Across Consumer Wellness Ecosystem

Indeterminate GlobeNewswire